Pulling SEC filings + quote and writing the call…
Pulling SEC filings + quote and writing the call…
BIO-TECHNE Corp
Next earnings ≈ Aug 5, 2026 · est. from filing cadence
Last earnings -16.4% on 2026-05-06
Revenue grew 5.2% YoY; but very expensive (P/E 122.4).
Rules-based read computed from SEC figures — no Anthropic key set. Add ANTHROPIC_API_KEY to .env.local for a full Claude analysis.
BIO-TECHNE Corp shows $1.22B in FY2025 revenue (+5.2% YoY), a 6.0% net margin, and 3.8% ROE.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro$19/mo · cancel anytime
Sources: SEC EDGAR (CIK 0000842023, latest 10-Q filed 2026-05-06) · EODHD · rules-based read · as of 6/17/2026, 6:05:56 PM.
Research and education only — not financial advice. Calls are generated from SEC filings and a delayed/third-party price feed, may be wrong or out of date, and are not a recommendation to buy or sell any security. Do your own research.
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $931M | $1.11B | $1.14B | $1.16B | $1.22B |
| Gross profit | $633M | $756M | $770M | $770M | $790M |
| Operating income | $237M | $297M | $299M | $207M | $102M |
| Net income | $140M | $272M | $285M | $168M | $73.4M |
| Diluted EPS | $0.87 | $1.66 | $1.76 | $1.05 | $0.46 |
| Net margin | 15.1% | 24.6% | 25.1% | 14.5% | 6.0% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
58 tracked peers · median
Source: EODHD. Yield = trailing-12-month dividends ÷ price.
Last 90 days: 0 open-market buys · 1 sale
| 2026-06-02 | Crouse Steven C. President - Diag & Spatial Bi | Exercise | 600.00 | |
| 2026-06-02 | Crouse Steven C. President - Diag & Spatial Bi | Tax | 216.00 @ $49.77 | $10.8K |
| 2026-05-08 | Herr Amy E. Director | Exercise | 6.64K @ $47.60 | $316K |
| 2026-05-08 | Herr Amy E. Director | Sell | 6.64K @ $48.28 | $320K |
| 2026-05-05 | Hippel James CFO | Exercise | 62.0K @ $47.60 | $2.95M |
| 2026-05-05 | Hippel James CFO | Tax | 57.0K @ $56.68 | $3.23M |
| 2026-05-05 | Bohnen Shane SVP - General Counsel | Exercise | 8.40K @ $47.60 | $400K |
| 2026-05-05 | Bohnen Shane SVP - General Counsel | Tax | 7.05K @ $56.68 | $400K |
| 2026-05-05 | Kelderman Kim Chief Executive Officer | Exercise | 26.7K @ $47.60 | $1.27M |
| 2026-05-05 | Kelderman Kim Chief Executive Officer | Tax | 24.0K @ $56.68 | $1.36M |
| 2026-05-01 | Crouse Steven C. President - Diag & Spatial Bi | Exercise | 794.00 | |
| 2026-05-01 | Crouse Steven C. President - Diag & Spatial Bi | Tax | 311.00 @ $55.02 | $17.1K |